Mona Alotaibi

Mona Alotaibi

Auto-generated profile, based on publicly available information

Mona Alotaibi

Division of Pulmonary, Critical Care and Sleep Medicine, University of California San Diego, La Jolla, CA, USA

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 August 2024 in European Respiratory Journal
Verified
Journal Article
Open access
PDF file
EAEric D. Austin
Eric D. Austin
MAMicheala A. Aldred
Micheala A. Aldred
MAMona Alotaibi
Mona Alotaibi
SGStefan Gräf
Stefan Gräf
WNWilliam C. Nichols
William C. Nichols
WCWendy K. Chung
Wendy K. Chung
Considerable progress has been made in the genomics of pulmonary arterial hypertension (PAH) since the 6th World Symposium on Pulmonary Hypertension, with the identification of rare variants in several novel genes, as well as common variants that confer a modest increase in PAH risk. Gene and variant curation by an expert panel now provides a robust framework for knowing which genes to test and how to interpret variants in clinical practice. We recommend that genetic testing be offered to specific subgroups of symptomatic patients with PAH, and to children with certain types of group 3 pulmonary hypertension (PH). Testing of asymptomatic family members and the use of genetics in reproductive decision-making require the involvement of genetics experts. Large cohorts of PAH patients with biospecimens now exist and extension to non-group 1 PH has begun. However, these cohorts are largely of European origin; greater diversity will be essential to characterise the full extent of genomic variation contributing to PH risk and treatment responses. Other types of omics data are also being incorporated. Furthermore, to advance gene- and pathway-specific care and targeted therapies, gene-specific registries will be essential to support patients and their families and to lay the foundation for genetically informed clinical trials. This will require international outreach and collaboration between patients/families, clinicians and researchers. Ultimately, harmonisation of patient-derived biospecimens, clinical and omic information, and analytic approaches will advance the field.

24 January 2025 in Science
Verified
Journal Article
Closed access
LHLloyd Harvey
Lloyd Harvey
MAMona Alotaibi
Mona Alotaibi
YTYi-Yin Tai
Yi-Yin Tai
YTYing Tang
Ying Tang
HKHee-Jung J. Kim
Hee-Jung J. Kim
SCStephen Chan
Stephen Chan
Vascular inflammation regulates endothelial pathophenotypes, particularly in pulmonary arterial hypertension (PAH). Dysregulated lysosomal activity and cholesterol metabolism activate pathogenic inflammation, but their relevance to PAH is unclear. Nuclear receptor coactivator 7 ( NCOA7 ) deficiency in endothelium produced an oxysterol and bile acid signature through lysosomal dysregulation, promoting endothelial pathophenotypes. This oxysterol signature overlapped with a plasma metabolite signature associated with human PAH mortality. Mice deficient for endothelial Ncoa7 or exposed to an inflammatory bile acid developed worsened PAH. Genetic predisposition to NCOA7 deficiency was driven by single-nucleotide polymorphism rs11154337, which alters endothelial immunoactivation and is associated with human PAH mortality. An NCOA7-activating agent reversed endothelial immunoactivation and rodent PAH. Thus, we established a genetic and metabolic paradigm that links lysosomal biology and oxysterol processes to endothelial inflammation and PAH.

9 February 2024 in Science Advances
Verified
Journal Article
Open access
ELElijah S. Lawrence
Elijah S. Lawrence
WGWanjun Gu
Wanjun Gu
RBRyan J. Bohlender
Ryan J. Bohlender
CACecilia Anza-Ramirez
Cecilia Anza-Ramirez
ACAmy M. Cole
Amy M. Cole
TSTatum S Simonson
Tatum S Simonson
Hypoxia-inducible factor pathway genes are linked to adaptation in both human and nonhuman highland species. EPAS1 , a notable target of hypoxia adaptation, is associated with relatively lower hemoglobin concentration in Tibetans. We provide evidence for an association between an adaptive EPAS1 variant (rs570553380) and the same phenotype of relatively low hematocrit in Andean highlanders. This Andean-specific missense variant is present at a modest frequency in Andeans and absent in other human populations and vertebrate species except the coelacanth. CRISPR-base-edited human cells with this variant exhibit shifts in hypoxia-regulated gene expression, while metabolomic analyses reveal both genotype and phenotype associations and validation in a lowland population. Although this genocopy of relatively lower hematocrit in Andean highlanders parallels well-replicated findings in Tibetans, it likely involves distinct pathway responses based on a protein-coding versus noncoding variants, respectively. These findings illuminate how unique variants at EPAS1 contribute to the same phenotype in Tibetans and a subset of Andean highlanders despite distinct evolutionary trajectories.

13 July 2022 in Chest
Verified
Journal Article
Open access
SWSheryl Wu
Sheryl Wu
HHHeather B. Hoang
Heather B. Hoang
JYJenny Z. Yang
Jenny Z. Yang
DPDemosthenes G. Papamatheakis
Demosthenes G. Papamatheakis
DPDavid S. Poch
David S. Poch
TFTimothy M. Fernandes
Timothy M. Fernandes
The management of pulmonary arterial hypertension (PAH) has become more complex in recent years because of increased pharmacotherapy options and longer patient survival with increasing numbers of comorbidities. As such, more opportunities exist for drug-drug interactions between PAH-targeted medications and medications potentially used to treat comorbid conditions. In this review, we provide an overview of pharmaceutical metabolism by cytochrome P450 and discuss important drug-drug interactions for the 14 Food and Drug Administration-approved medications for PAH in the nitric oxide (NO), endothelin, and prostacyclin pathways. Among the targets in the NO pathway (sildenafil, tadalafil, and riociguat), important interactions with nitrates, protease inhibitors, and other phosphodiesterase inhibitors can cause profound hypotension. In the endothelin pathway, bosentan is associated with more drug interactions via CYP3A4 inhibition; macitentan and ambrisentan have fewer interactions of note. Although the parenteral therapies in the prostacyclin pathway bypass significant liver metabolism and avoid drug interactions, selexipag and oral treprostinil may exhibit interactions with CYP2C8 inhibitors such as gemfibrozil and clopidogrel, which can raise drug levels. Finally, we provide a framework for identifying potential drug-drug interactions and avoiding errors.

19 October 2023 in European Respiratory Journal
Verified
Journal Article
Open access
PDF file
JMJenna N. McNeill
Jenna N. McNeill
ARAthar Roshandelpoor
Athar Roshandelpoor
MAMona Alotaibi
Mona Alotaibi
ACArrush Choudhary
Arrush Choudhary
MJMohit Jain
Mohit Jain
JHJennifer E. Ho
Jennifer E. Ho
Background: Eicosanoids are bioactive lipids that regulate systemic inflammation and exert vasoactive effects. Specific eicosanoid metabolites have previously been associated with pulmonary hypertension (PH), yet their role remains incompletely understood.Methods: We studied 482 participants with chronic dyspnoea who underwent clinically indicated cardiopulmonary exercise testing (CPET) with invasive haemodynamic monitoring. We performed comprehensive profiling of 888 eicosanoids and eicosanoid-related metabolites using directed non-targeted mass spectrometry, and examined associations with PH (mean pulmonary arterial pressure (mPAP) >20 mmHg), PH subtypes and physiological correlates, including transpulmonary metabolite gradients.Results: Among 482 participants (mean±sdage 56±16 years, 62% women), 200 had rest PH. We found 48 eicosanoids and eicosanoid-related metabolites that were associated with PH. Specifically, prostaglandin (11β-dhk-PGF2α), linoleic acid (12,13-EpOME) and arachidonic acid derivatives (11,12-DiHETrE) were associated with higher odds of PH (false discovery rate q<0.05 for all). By contrast, epoxide (8(9)-EpETE), α-linolenic acid (13(S)-HOTrE(γ)) and lipokine derivatives (12,13-DiHOME) were associated with lower odds. Among PH-related eicosanoids, 14 showed differential transpulmonary metabolite gradients, with directionality suggesting that metabolites associated with lower odds of PH also displayed pulmonary artery uptake. In individuals with exercise PH, eicosanoid profiles were intermediate between no PH and rest PH, with six metabolites that differed between rest and exercise PH.Conclusions: Our findings highlight the role of specific eicosanoids, including linoleic acid and epoxide derivatives, as potential regulators of inflammation in PH. Of note, physiological correlates, including transpulmonary metabolite gradients, may prioritise future studies focused on eicosanoid-related pathways as important contributors to PH pathogenesis.

1 March 2021 in Structural Heart
Verified
Journal Article
Open access
W. Cameron McGuireW. Cameron McGuire
W. Cameron McGuire
MAMona Alotaibi
Mona Alotaibi
TMTimothy A. Morris
Timothy A. Morris
NKNick H. Kim
Nick H. Kim
TFTimothy M. Fernandes
Timothy M. Fernandes
Recovery after acute pulmonary embolism occurs on a continuum from complete restoration of flow to persistent perfusion defects causing pulmonary hypertension. An under-recognized complication of pulmonary embolism is chronic thromboembolic disease (CTED), a condition characterized by abnormal perfusion but no resting pulmonary hypertension. These patients often present with dyspnea on exertion. In this review, we discuss the epidemiology of CTED and the physiologic reasons that dyspnea on exertion manifests, namely increased dead space ventilation and exercise-induced pulmonary hypertension. We present the protocol used for invasive cardiopulmonary exercise testing with right heart catheterization necessary to differentiate these two phenotypes of CTED and exclude other causes of dyspnea on exertion such as exercise-induced diastolic dysfunction. Finally, we discuss the potential management options for symptomatic CTED including pulmonary thromboendarterectomy and balloon pulmonary angioplasty.